3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 4
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Colorectal Neoplasms
36
Pancreatic Neoplasms
26
Rectal Neoplasms
15
Esophageal Neoplasms
13
Colonic Neoplasms
12
Stomach Neoplasms
11
Squamous Cell Carcinoma of Head and Neck
11
Neoplasm Metastasis
8
Gastrointestinal Neoplasms
8
Esophageal Squamous Cell Carcinoma
7
Adenocarcinoma Of Esophagus
7
Neoplasms
6
Head and Neck Neoplasms
5
Carcinoma, Squamous Cell
5
Carcinoma, Non-Small-Cell Lung
5
Biliary Tract Neoplasms
5
Carcinoma, Hepatocellular
4
Advanced Solid Tumors
4
Melanoma
3
Liver Neoplasms
3
Carcinoma, Renal Cell
3
Adenocarcinoma
3
Triple Negative Breast Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Oropharyngeal Neoplasms
2
Kidney Neoplasms
2
Gastrointestinal Diseases
2
Endometrial Neoplasms
2
Carcinoma
2
Interventions
pembrolizumab
3
fludarabine
3
Cyclophosphamide
3
Ipilimumab
2
smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic
1
sargramostim
1
reolysin
1
poly ICLC
1
peginterferon alfa-2a
1
osimertinib
1
gusacitinib
1
fludarabine phosphate
1
eprenetapopt
1
epacadostat
1
dabrafenib
1
cobimetinib
1
cemiplimab
1
Vorinostat
1
Temozolomide
1
Radiotherapy
1
Radiation
1
Poly I-C
1
Nivolumab
1
Monatide (IMS 3015)
1
Methods
1
MAPRE1 protein, human
1
Interleukin-2
1
Interleukin-15
1
Interleukin-12
1
IT-101
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Skin Neoplasms
×
Fluorouracil
×
Clear all
NCT02550678
2018-06-06
ASN-002-001
Ascend Biopharmaceuticals Ltd
Phase 1/2
Completed
16 enrolled